| abstract |
The present invention relates to a progesterone receptor antagonist 11β (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9-dien-3-one Or a pharmaceutically acceptable derivative or analog thereof and at least one pure non-steroidal anti-estrogen and the use of the combination for the prevention and treatment of BRCA1 or BRCA2 mediated diseases. Used in combination with the progesterone receptor antagonist 11β (4-acetylphenyl) -17β-hydroxy-17α- (1,1,2,2,2-pentafluoroethyl) -estradi-4,9-dien-3-one Possible nonsteroidal antiestrogens are tamoxifen, raloxifene, droloxifene, toremifene, lasofoxifene, arzoxifene, GW5638, EM-800, idoxifene, and basedoxifene. [Selection figure] None |